Aili L. Lazaar
Department of Medicine
Hospital of University of Pennsylvania
Philadelphia 19104
USA
Name/email consistency: high
- Technology evaluation: omalizumab, Genentech/Novartis/Tanox. Lazaar, A.L. Curr. Opin. Mol. Ther. (2003)
- Is airway remodeling clinically relevant in asthma?. Lazaar, A.L., Panettieri, R.A. Am. J. Med. (2003)
- Mast cell chymase modifies cell-matrix interactions and inhibits mitogen-induced proliferation of human airway smooth muscle cells. Lazaar, A.L., Plotnick, M.I., Kucich, U., Crichton, I., Lotfi, S., Das, S.K., Kane, S., Rosenbloom, J., Panettieri, R.A., Schechter, N.M., Puré, E. J. Immunol. (2002)
- Airway smooth muscle: new targets for asthma pharmacotherapy. Lazaar, A.L. Expert Opin. Ther. Targets (2002)
- VCAM-1 activates phosphatidylinositol 3-kinase and induces p120Cbl phosphorylation in human airway smooth muscle cells. Lazaar, A.L., Krymskaya, V.P., Das, S.K. J. Immunol. (2001)
- Airway smooth muscle as an immunomodulatory cell: a new target for pharmacotherapy?. Lazaar, A.L., Panettieri, R.A. Curr. Opin. Pharmacol (2001)
- CD40-mediated signal transduction in human airway smooth muscle. Lazaar, A.L., Amrani, Y., Hsu, J., Panettieri, R.A., Fanslow, W.C., Albelda, S.M., Puré, E. J. Immunol. (1998)